XNCR

• Focused pipeline and discovery work on T-cell engagers for solid tumors, with updates on vudalimab in prostate cancer (monotherapy cohort with encouraging responses) and initiation of a front-line non-small cell lung cancer study. • Partnerships with Amgen, including promising data from Xaluritamig in late-line prostate cancer. • Progress on XmAb bispecifics: XmAb819 (ENPP3 in renal cell carcinoma) advancing in dose escalation; XmAb808 (CD28 targeting) in Phase 1; XmAb541 (CLDN6) to start Phase 1 in H1 2024. • Strengthened balance sheet with partial monetization of royalties, ending 2023 with $697 million and runway into 2027. • Wrapping up Phase 1 work for XmAbs 564 and 662, focusing resources on T-cell engagers.

• 2024 priorities focus on solid tumor bispecifics pipeline. • Intend to select next IND candidate later in 2024.

No specific segment performance data on absolute terms and revenue contribution provided in the transcript.

Forward-looking statements subject to known and unknown risks, uncertainties, and factors from the company's most recently filed annual report on Form 10-K, but no specific operational failures detailed in the Q&A.

Q: Comment on when initial clinical data from ENPP3 study might be seen.

A: Bassil stated they are working on characterizing the dose and will disclose when close to having data to share.

Q: Bar for go-forward decisions on vudalimab mono and combo.

A: Dane discussed comparing with peer studies, with RECIST response and deep PSA response as key factors.

Q: Safety of vudalimab, including autoimmune hepatitis and pause of XmAb564.

A: Bassil said XmAb564 pause was strategy-driven due to focus on T-cell engagers; Nancy discussed the single hepatitis case and monitoring protocols.

Q: Monotherapy data molecular subtype, PSA comparison.

A: Bassil said the monotherapy study isn't subdivided by molecular subtype; Dane explained PSA differences due to measurable disease vs. bone-only patients.

Q: Safety vs IPI/NIVO, dose going forward, enrollment numbers, bone responses.

A: Nancy said vudalimab safety is similar to other checkpoint inhibitors; dose is Q3 week flat; aiming for ~30 patients in monotherapy and combo cohorts.

Q: Background of confirmed responders, low-hanging fruit in mCRPC.

A: Nancy discussed heavily pretreated patients; Dane talked about comparators and future combination possibilities.

Q: Benchmark for vudalimab monotherapy, quality-of-life data.

A: Dane said waiting for cohort totals and using peer studies as comparators, with future plans to evaluate quality-of-life once cohorts are larger